Orion Oyj (HEL:ORNBV)

Market Cap	7.87B
Revenue (ttm)	1.54B
Net Income (ttm)	329.90M
Shares Out	140.50M
EPS (ttm)	2.35
PE Ratio	23.88
Forward PE	22.18
Dividend	1.64 (2.88%)
Ex-Dividend Date	Apr 4, 2025

Volume	20,516
Average Volume	220,711
Open	56.98
Previous Close	56.86
Day's Range	56.72 - 57.48
52-Week Range	31.86 - 57.70
Beta	0.35
RSI	63.71
Earnings Date	Feb 25, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNBV

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.